RxDoctor Payments Data

Katherine Kedzierski, MD

Neurology · Waterbury, CTNPI 1548571110

Payments from drug & device makers

$11,662in general payments, 2019–2025

Across 609 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • SK Life Science, Inc.$749
  • Argenx US, Inc.$586
  • Lilly USA, LLC$438
  • Neurocrine Biosciences, Inc.$387
  • AstraZeneca$379
  • plus $5K from 45 others

What the payments were for

  • Speaking & faculty fees$1301%
  • Food & beverage$11,43698%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,662 in reported general payments places this provider in the 70th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$149,637
Medicare patients
446
Services billed
4,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant59$68,816
Nurtec OdtRimegepant Sulfate46$64,495
UbrelvyUbrogepant40$40,392
Memantine Hcl ErMemantine Hcl450$37,565
Emgality PenGalcanezumab-Gnlm27$18,590
Pregabalin24$2,584
Gabapentin150$2,413
Carbamazepine ErCarbamazepine22$2,364
Levetiracetam108$1,816
Donepezil Hcl OdtDonepezil Hcl119$1,648
Carbidopa-LevodopaCarbidopa/Levodopa172$1,557
Lacosamide21$1,289
Sumatriptan Succinate89$1,103
Primidone60$1,023
Donepezil Hcl131$1,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$3,792$109,20899 claims
PfizerNurtec Odt$220$64,49546 claims
Upsher-smith Laboratories LLCTopiramate$36$51850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 280 neurology providers in Connecticut.

Other neurology in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →